BR112022011563A2 - 4-((2-oxopiridin-1 (2h)-il)metil)benzamidas para tratamento de deficiência de alfa1-antitripsina - Google Patents

4-((2-oxopiridin-1 (2h)-il)metil)benzamidas para tratamento de deficiência de alfa1-antitripsina

Info

Publication number
BR112022011563A2
BR112022011563A2 BR112022011563A BR112022011563A BR112022011563A2 BR 112022011563 A2 BR112022011563 A2 BR 112022011563A2 BR 112022011563 A BR112022011563 A BR 112022011563A BR 112022011563 A BR112022011563 A BR 112022011563A BR 112022011563 A2 BR112022011563 A2 BR 112022011563A2
Authority
BR
Brazil
Prior art keywords
alpha1
treatment
oxopiridin
benzamides
methyl
Prior art date
Application number
BR112022011563A
Other languages
English (en)
Inventor
Nigel Ramsden Dr
David John Fox Dr
James Andrew Huntington Prof
James Michael Tomlinson Dr
Original Assignee
Z Factor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Z Factor Ltd filed Critical Z Factor Ltd
Publication of BR112022011563A2 publication Critical patent/BR112022011563A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

“4-((2-OXOPIRIDIN-1 (2H)-IL)METIL)BENZAMIDAS PARA TRATAMENTO DE DEFICIÊNCIA DE ALFA1-ANTITRIPSINA. A invenção refere-se a cinco compostos de benzamida de fórmula (1) e a composições farmacêuticas que contêm os compostos. Os compostos podem ser indutores de alfa1-antitripsina (A1AT) e podem ser usados no tratamento de uma doença ou distúrbio como deficiência de alfa1-antitripsina (A1AD ou AATD).
BR112022011563A 2019-12-13 2020-12-11 4-((2-oxopiridin-1 (2h)-il)metil)benzamidas para tratamento de deficiência de alfa1-antitripsina BR112022011563A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1918413.4A GB201918413D0 (en) 2019-12-13 2019-12-13 Compounds and their use for the treatment of alpha1-antitrypsin deficiency
PCT/GB2020/053192 WO2021116707A1 (en) 2019-12-13 2020-12-11 4-((2-oxopyri din-1 (2h)-yl)methyl)benzamides for treating alpha1 -antitrypsin deficiency

Publications (1)

Publication Number Publication Date
BR112022011563A2 true BR112022011563A2 (pt) 2022-08-30

Family

ID=69186725

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011563A BR112022011563A2 (pt) 2019-12-13 2020-12-11 4-((2-oxopiridin-1 (2h)-il)metil)benzamidas para tratamento de deficiência de alfa1-antitripsina

Country Status (12)

Country Link
US (1) US20230129181A1 (pt)
EP (1) EP4073040A1 (pt)
JP (1) JP2023506496A (pt)
KR (1) KR20220127824A (pt)
CN (1) CN115023416B (pt)
AU (1) AU2020401453A1 (pt)
BR (1) BR112022011563A2 (pt)
CA (1) CA3164302A1 (pt)
GB (1) GB201918413D0 (pt)
IL (1) IL293786A (pt)
MX (1) MX2022007176A (pt)
WO (1) WO2021116707A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820450D0 (en) * 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
WO2022263829A1 (en) * 2021-06-16 2022-12-22 Z Factor Limited COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334990T3 (es) 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
BRPI0409227C1 (pt) * 2003-04-07 2021-05-25 Axys Pharm Inc composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
ES2529147T3 (es) * 2006-12-26 2015-02-17 Pharmacyclics, Inc. Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
EP2114141A2 (en) 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
WO2011056222A1 (en) * 2009-11-05 2011-05-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein aggregation
WO2015155306A1 (en) * 2014-04-11 2015-10-15 Almirall, S.A. New trpa1 antagonists
SG11202012765PA (en) 2018-06-22 2021-01-28 Ucl Business Ltd Novel compounds
MA53827A (fr) 2018-10-05 2021-09-15 Vertex Pharma Modulateurs de l'alpha -1 antitrypsine
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina

Also Published As

Publication number Publication date
AU2020401453A1 (en) 2022-07-21
CN115023416B (zh) 2024-04-02
CN115023416A (zh) 2022-09-06
JP2023506496A (ja) 2023-02-16
MX2022007176A (es) 2022-08-25
IL293786A (en) 2022-08-01
GB201918413D0 (en) 2020-01-29
KR20220127824A (ko) 2022-09-20
EP4073040A1 (en) 2022-10-19
WO2021116707A1 (en) 2021-06-17
CA3164302A1 (en) 2021-06-17
US20230129181A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112022011563A2 (pt) 4-((2-oxopiridin-1 (2h)-il)metil)benzamidas para tratamento de deficiência de alfa1-antitripsina
EA201691847A1 (ru) Способы снижения сердечно-сосудистого риска
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
BR112017012327A8 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112017017009A2 (pt) usos de um sequestrante de formaldeído e de uma composição farmacêutica, métodos para impedir, adiar, retardar ou diminuir a transformação de um composto e para tratar câncer, e, composição farmacêutica.
MA38398A1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
EA201691375A1 (ru) (2s)-n-[(1s)-1-циано-2-фенилэтил]-1,4-оксазепан-2-карбоксамиды в качестве ингибиторов дипептидилпептидазы i
BR112017004708A2 (pt) terapia de combinação de cenicriviroc para o tratamento de fibrose
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
EA200870218A1 (ru) Замещенные имидазольные производные, композиции и способы применения в качестве ингибиторов ртразы
BR112013027034A8 (pt) "compostos para o tratamento de transtornos neuropsiquiátricos."
BR112022010319A2 (pt) Uso de bi853520 no tratamento de câncer
BR112017016428A2 (pt) ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?
BR112016030730A8 (pt) composto
BR112021021826A8 (pt) Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4
BR112012005511B8 (pt) 5-(3,4-dicloro-fenil)-n-(2-hidróxi-ciclo-hexil)-6-(2,2,2-triflúor-etóxi-)-nicotinamida e sais da mesma como agentes de elevação de colesterol hdl
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
BR112022011548A2 (pt) Compostos e uso dos mesmos para o tratamento da deficiência de a1-antitripsina
BR112022011566A2 (pt) Compostos e uso dos mesmos para o tratamento de deficiência de a1-antitripsina
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
EA201991490A1 (ru) Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1